ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ADC Therapeutics secures FDA priority review for Lonca in diffuse large B-cell lymphoma
November 24, 2020ADC Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and ... -
ADC Therapeutics begins phase 2 portion of LOTIS 3 trial of Lonca, ibrutinibhave combo
July 22, 2020ADC Therapeutics announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed ...
Pharma Sources Insight January 2025
